Choate Radmila, Sandhaus Robert A, Holm Kristen E, Mannino David M, Strange Charlie
College of Public Health, University of Kentucky, Lexington, Kentucky, United States.
Department of Medicine, National Jewish Health, Denver, Colorado, United States.
Chronic Obstr Pulm Dis. 2022 Oct 26;9(4):549-561. doi: 10.15326/jcopdf.2022.0317.
Identifying pulmonary exacerbations in patients with alpha-1 antitrypsin deficiency (AATD) is critical as they are associated with disease progression and poor health-related quality of life. Not all changes in usual respiratory symptoms will be identified as exacerbations by patients with AATD.
Data collected via regular monthly telephone calls during the first year of the AlphaNet Step Forward Study were analyzed. AlphaNet subscribers were asked about changes in their usual respiratory symptoms, whether they considered changes in symptoms to be pulmonary exacerbations, and their management. Participants who reported changes in their usual respiratory symptoms throughout the year were included in the study. Per-patient and per-event analyses were performed.
Participants (n=316, age 58±10 years, 53% female) reported 797 events of changes in their usual respiratory symptoms in 1 year. Almost half (48%) of these symptom events were identified as pulmonary exacerbations by the study participants. The average number of symptoms was higher in events recognized by participants as exacerbations than those not identified as exacerbations (3.3±1.5 versus 1.8±1.1, respectively). A greater proportion of the exacerbation events were managed by taking antibiotics or corticosteroids or both (81%, 53%, and 41% of the events, respectively). With exacerbations, participants mainly spoke to the pulmonary specialist (39%) or went to the doctor's office (37%). Symptom events not recognized as exacerbations were mostly self-treated (56%).
Changes in usual pulmonary symptoms are not universally recognized as exacerbations. Patients' perspectives in recognizing changes in pulmonary symptoms as exacerbation events are critical.
识别α-1抗胰蛋白酶缺乏症(AATD)患者的肺部加重情况至关重要,因为它们与疾病进展和健康相关生活质量差有关。并非所有常见呼吸道症状的变化都会被AATD患者识别为加重情况。
对在AlphaNet向前迈进研究的第一年通过每月定期电话收集的数据进行分析。询问AlphaNet订阅者其常见呼吸道症状的变化、他们是否认为症状变化是肺部加重情况以及他们的处理方式。纳入全年报告常见呼吸道症状有变化的参与者。进行了 per - 患者和 per - 事件分析。
参与者(n = 316,年龄58±10岁,53%为女性)报告在1年中有797次常见呼吸道症状变化事件。这些症状事件中近一半(48%)被研究参与者识别为肺部加重情况。参与者识别为加重情况的事件中的症状平均数量高于未被识别为加重情况的事件(分别为3.3±1.5和1.8±1.1)。更大比例的加重情况事件通过服用抗生素或皮质类固醇或两者来处理(分别占事件的81%、53%和41%)。出现加重情况时,参与者主要与肺部专科医生沟通(39%)或前往医生办公室(37%)。未被识别为加重情况的症状事件大多是自我处理(56%)。
常见肺部症状的变化并非都被普遍识别为加重情况。患者将肺部症状变化识别为加重事件的观点至关重要。